WILMINGTON, Del., March 12, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:
-
Do you own shares of Spark Therapeutics, Inc. (NASDAQ GS: ONCE)?
- Did you purchase any of your shares prior to February 25, 2019?
- Do you think the proposed buyout is fair?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against
the board of directors of Spark Therapeutics, Inc. (“Spark” or the “Company”) (NASDAQ GS: ONCE) regarding possible breaches of fiduciary duties and other violations of law related to the
Company’s entry into an agreement to be acquired by Roche Holding Ltd. (“Roche”) (OTCQX: RHHBY), in a transaction valued at approximately $4.8 billion. Under the terms of the agreement,
shareholders of Spark will receive $114.50 in cash for each share of Spark common stock.
If you own common stock of Spark and purchased any shares before February 25, 2019, if you would like to learn more about this
investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D.
Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered
hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases
nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative
actions.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT:
Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com
